PA-EXONE
11.11.2021 14:33:09 CET | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced that the Schunk Group, an international technology company featuring products made of high-tech materials, including sintered metals, has purchased an X1 25Pro large metal binder jetting system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005667/en/
The new X1 25Pro metal printing system will be installed and used in the Schunk Sinter Metals location in Thale, Germany, to provide serial production of sintered metal parts to automotive, aerospace, medical, and other customers throughout Europe – starting with 316L stainless steel and later expanding to other materials.
“We believe 3D printing is the technology of the future, and we will use our binder jetting system to develop technologies and parts that go beyond what we can provide with traditional sintered metal components,” said Tobias Franz Heusel, Global Account Manager at Schunk.
Schunk plans to integrate its ExOne metal binder jetting technology into its industrial ecosystem that already includes other methods of 3D printing producing parts with different materials such as copper, stainless steel and low alloyed steel, as well as conventional manufacturing processes such as axial pressing and metal injection molding. “We believe binder jetting offers four primary advantages. In addition to speed and freedom of design, the ability to produce large volumes with 3D printing and a large selection of materials is fairly unique among 3D printing processes,” Heusel added.
Schunk selected ExOne as its binder jet partner, largely because of the company’s extensive history as the commercial pioneer and market leader in metal binder jetting. Over its history, ExOne has launched more than 10 commercial metal binder jetting systems.
“We are proud to partner with Schunk to provide ExOne binder jet 3D printing services in the European market,” said Eric Bader, Managing Director, ExOne, EMEA. “Schunk’s services will complement our own ExOne Adoption Center (EAC) in Gersthofen, where we will provide benchmarks to customers interested in purchasing machines.”
Details about Schunk’s move into binder jet 3D printing can be found at https://bit.ly/SchunkX1en
What is Binder Jet 3D Printing?
ExOne’s binder jet 3D printing transforms powdered materials – metal, sand or ceramic – into highly dense and functional precision parts at high speeds.
An industrial printhead selectively deposits a binder into a bed of powder particles creating a solid part one thin layer at a time. When printing metals, the final bound metal part must be sintered in a furnace to fuse the particles together into a solid object. ExOne now delivers high densities of greater than 97% for most metals, in line with Metal Injection Molding or gravity castings.
Binder jet 3D printing technology is viewed as a desirable and sustainable production method, largely because of its high speed, low waste and cost, as well as material flexibility.
About ExOne
ExOne (Nasdaq: XONE) is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
Schunk Group
The Schunk Group is a global technology company. The company is a leading supplier of products made of high-tech materials – such as carbon, technical ceramics and sintered metal – as well as machines and systems – from environmental simulation and air conditioning to ultrasonic welding and optical machines. The Schunk Group has around 9,000 employees in 29 countries and achieved sales of €1.2 billion in 2020. Learn more at www.schunk-group.com or on LinkedIn @Schunk Group.
With over 90 years of experience in powder metallurgy, the business unit Schunk Sinter Metals is the technology and development partner for the automotive and aerospace industries when it comes to the production of sintered metal parts by axial pressing, metal powder injection molding and additive manufacturing processes. Learn more at www.schunk-mobility.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005667/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
